The EasyNAT Malaria Assay is a highly effective molecular tool for the rapid detection of Plasmodium species, utilizing isothermal cross-priming amplification (CPA). It demonstrates superior sensitivity compared to traditional microscopy and RDTs, particularly in detecting low-parasitemia infections in patients who have already self-medicated. With its user-friendly, fully automated cartridge system and a turnaround time of just 50 minutes, it is an ideal solution for emergency room screenings and high-risk population monitoring. While it cannot yet differentiate between malaria species, its accuracy and ease of use make it a promising frontline diagnostic for clinical practice.

"6M GTC can liquefy sputum and render MTB non-viable, eliminating the need for Mycobacterium nucleic acid testing in BSL-2 laboratories; the newly established CPA method can rapidly and accurately distinguish MTB and NTM in the form of POCT, with simple and fast operation, suitable for promotion and application in grassroots medical institutions and remote rural areas."

"EasyNAT MP is suitable as an initial test for MP diagnosis due to its simplicity, low turnaround time, and high sensitivity and specificity."

"To summarize, the STI CNM Real-Time PCR Kit developed by Vitro S.A. proves to be extremely valuable in identifying N. gonorrhoeae, C. trachomatis, and M. genitalium in various clinical samples, including urine, urethral, rectal, vaginal, endocervical and pharyngeal swabs. One of its key advantages is adopting a syndromic diagnostic approach, streamlining the sample processing procedure in the laboratory, expediting result delivery, and optimizing resource utilization. With its remarkable sensitivity and specificity, this kit is highly recommended for routine use in clinical laboratories as it consistently provides reliable results, thereby facilitating the effective management of sexually transmitted infections. Moreover, the kit’s capability to simultaneously detect the three primary causative agents of ure-thritis/cervicitis through a single multiplex PCR reaction, coupled with the substantial reduction in economic costs observed in our laboratory, further underscores its practicality and convenience in the clinical setting."

"This study demonstrates substantial variability in intrapartum GBS detection when assays are used under real-world conditions without prior enrichment, with positive percent agreement ranging from 0.0% to 80.6%. These results indicate that performance cannot be assumed equivalent across platforms, even when based on similar amplification technologies. Our data further suggest that pre-analytical factors, particularly the efficiency of bacterial lysis, may play a key role in determining sensitivity in direct testing conditions. In a context where new molecular POCT platforms are rapidly emerging, these observations underline the responsibility of clinical laboratories to independently and rigorously evaluate such systems prior to implementation, as their analytical reliability may vary considerably and may not always meet clinical requirements."

"In summary, the Pluslife assay shows good consistency with RT-qPCR. Compared with the EasyNAT assay, the Pluslife assay exhibits the same excellent detection efficiency of SARS-CoV-2 positive samples, with smaller size, lower cost, and faster detection speed. Compared with the Wondfo assay, the clinical performance of the Pluslife assay is more prominent, with a lower false-negative rate. The Pluslife Mini Dock’s compact design, portability, simple operation, rapid detection, capacity, and cost-effectiveness support its use for SARS-CoV-2 screening in resource-limited settings."

The Dragonfly platform provides a rapid, portable, and low-cost molecular diagnostic solution for mpox and similar skin-tropic viruses. By combining power-free nucleic acid extraction with colorimetric LAMP technology, the system delivers a "sample-to-result" workflow in under 40 minutes without requiring complex laboratory equipment, a cold chain, or specialized training. Validated with 164 clinical samples, the platform achieved 94.1% sensitivity and 100% specificity for the monkeypox virus. It effectively differentiates mpox from other orthopoxviruses, HSV-1, HSV-2, and VZV, addressing a critical gap in point-of-care (POC) diagnostics. This robust, scalable technology aligns with WHO goals for early case detection and outbreak management in both high- and low-resource settings.

"In conclusion, this study provides the first clinical evaluation of the EasyNAT Rapid Flu assay for influenza virus detection, comparing it to real-time RT-PCR and the Xpert Xpress Flu/RSV assay. The assay demonstrates excellent agreement with these RT-PCR-based assays, offering a fast solution. With its demonstrated good diagnostic performance, the EasyNAT Rapid Flu assay shows promising potential in aiding accurate diagnosis of influenza."

"Because of the complexity of detecting RIF resistance data information, the rapid EasyNAT system used in conjunction with GeneXpert might be a better choice for the detection of TB in hospitals."

"In conclusion, the EasyNAT assay had a similar diagnostic capacity for MTB in GA samples compared with the Xpert assay in children but demonstrated a lower sensitivity than Xpert Ultra. EasyNAT may therefore be useful as a suitable alternative method of childhood TB diagnosis based on its cost-effectiveness, speed, and accuracy."

"Based on the features of the EasyNAT assay, we speculate that EasyNAT could be used as an initial test for diagnosing TB. Its high sensitivity, rapid turnaround time, and lower cost make EasyNAT a practical yet effective choice in low and middleincome countries for point-of-case testing. However, further validations in different settings are needed to justify this assumption."

The study concludes that a simple, stepwise approach - combining professional instruction with sputum induction - significantly increases bacteriological confirmation rates for tuberculosis compared to unobserved collection. These findings suggest that implementing standardized, assisted collection protocols in resource-limited primary care clinics can effectively bridge diagnostic gaps and improve TB detection across smear, culture, and molecular assays.

"The EasyNAT SARS-CoV-2-Assay technique has demonstrated satisfactory performance, especially when the sample used was fresh or exhibited elevated viral loads (Ct value below 30)."

"For further work on the development and use of LAMP tests for Buruli diagnosis, it is recommended that the BURULI sets of primers be used, as these yielded the best results in terms of sensitivity (87.50-91.49%) and specificity (89.23-100%), depending on the DNA extraction methods used."